drugset / Trial / NCT00510445
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to patients with advanced or metastatic non-small cell lung cancer.
Timeline
- Start
- 2007-07
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imetelstat | Oligonucleotide (other) | 3.2 mg/kg | — |
| Subject | Imetelstat | Oligonucleotide (other) | 4.8 mg/kg | — |
| Subject | Imetelstat | Oligonucleotide (other) | 6 mg/kg | — |
| Subject | Imetelstat | Oligonucleotide (other) | 7.5 mg/kg | — |
| Subject | Imetelstat | Oligonucleotide (other) | 9 mg/kg | — |
| Subject | Imetelstat | Oligonucleotide (other) | 11 mg/kg | — |
| Subject | Imetelstat | Oligonucleotide (other) | 13.5 mg/kg | — |